ASXL1 and colorectal cancer: However, ASXL1 amplifications appear to be reasonably common in solid tumors and are present in >20% of uterine carcinosarcomas and ∼10% of colorectal cancers, according to TCGA data (Cancer Genome Atlas 2012; Zhao et al. 2016).